

THE GLOBAL INFLUENZA MARKET



PHM049D
March 2017

Melissa Elder
Project Analyst

ISBN: 1-62296-465-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES	2
RELATED BCC RESEARCH REPORTS	3
ANALYST'S CREDENTIALS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY	6
<i>SUMMARY TABLE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 (\$ MILLIONS)</i>	7
CHAPTER 3 INDUSTRY OVERVIEW	9
OVERVIEW	9
HISTORY OF THE MARKET	9
EPIDEMICS/PANDEMICS	9
Spanish Influenza 1918-1919	9
Hong Kong Influenza 1968	10
Asian Influenza 1957	10
Swine Flu 1976	10
Russian Influenza 1977	10
Avian Flu 1961, 1997, 2003-2009/2010 (sporadic)	10
Novel Influenza H1N1 2009	11
<i>TABLE 1 DISTRIBUTION OF FATAL CASES OF H1N1 PANDEMIC BY WHO REGIONS, 2009-2010</i>	11
CDC Reported 2009 H1N1 Cases in the U.S.	12
<i>TABLE 2 CDC ESTIMATES OF 2009 H1N1 CASES AND RELATED HOSPITALIZATIONS AND DEATHS, BY AGE GROUP, APRIL 2009 - MARCH 13, 2010</i>	12
Influenza H7N9 2013	12
<i>TABLE 3 CUMULATIVE NUMBER OF CONFIRMED CASES OF H7N9, BY REGION, OCTOBER 2016</i>	13
VIRUS MUTATIONS	13
TYPES OF INFLUENZA	14
Influenza Type A	14
Influenza Type B	15
Influenza Type C	15
WORLD ACTIVITY OF INFLUENZA VIRUSES	15
<i>FIGURE 1 WORLDWIDE INFLUENZA ACTIVITY OCTOBER 2014 - MAY 2015</i>	16
<i>FIGURE 2 WORLDWIDE INFLUENZA ACTIVITY MAY 2015 - SEPTEMBER 2015</i>	16
THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE	17
WORLD HEALTH ORGANIZATION	17

TOPIC	PAGE NO.
CENTERS FOR DISEASE CONTROL AND PREVENTION	17
U.S. VIRAL SURVEILLANCE	18
<i>TABLE 4 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)</i>	18
<i>FIGURE 3 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)</i>	19
FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE AND VACCINE COMPOSITION	19
<i>TABLE 5 INFLUENZA VIRUS RECOMMENDATIONS FOR U.S. INFLUENZA SEASONS, 2003-2017</i>	20
VACCINE RECOMMENDATIONS	20
<i>TABLE 6 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)</i>	22
<i>TABLE 7 CDC INFLUENZA VACCINE RECOMMENDATIONS FOR ALL PEOPLE FROM 6 MONTHS OF AGE</i>	23
<i>FIGURE 4 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS ALLERGIC TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES FOR U.S. INFLUENZA SEASON, 2015-2016</i>	24
VACCINE EFFECTIVENESS	24
<i>TABLE 8 ADJUSTED VACCINE EFFECTIVENESS ESTIMATES FOR INFLUENZA SEASONS, 2005-2016</i>	25
UNIVERSAL VACCINE	26
INFLUENZA PREPAREDNESS AND RAPID PRODUCTION	27
POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY	27
GLOBAL DEMOGRAPHICS	27
<i>TABLE 9 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)</i>	28
<i>FIGURE 5 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)</i>	28
<i>TABLE 10 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)</i>	29
<i>FIGURE 6 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)</i>	29
<i>TABLE 11 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2020</i>	29
<i>FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010- 2020 (MILLIONS)</i>	30
GLOBAL LIFE EXPECTANCY	31
<i>TABLE 12 GLOBAL LIFE EXPECTANCY AT BIRTH, BY SELECTED COUNTRY, 1980-2020 (YEARS)</i>	31
<i>FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2020 (YEARS)</i>	31
INFLUENZA INCIDENCE AND MORTALITY	32
<i>TABLE 13 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP, APRIL 2009-2010</i>	32
CHAPTER 4 ISSUES AFFECTING THE MARKET	36
H1N1 OUTBREAK 2009 (SWINE FLU)	36
RAPID DIAGNOSTICS	36
Pandemic Testing	36
Seasonal Influenza Tests	37
AVIAN FLU	37
<i>TABLE 14 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS</i>	37
AVIAN FLU SURVEILLANCE	38

TOPIC	PAGE NO.
<i>TABLE 15 WHO-REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS</i>	39
<i>FIGURE 9 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS, 2003-2016* (NO.)</i>	39
The WHO and Containment for Pandemic Influenza	40
<i>FIGURE 10 APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)</i>	40
INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS	41
PRE-PANDEMIC VACCINATION	42
<i>FIGURE 11 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS FOR SELECTED COUNTRIES (MILLION)</i>	42
Biomedical Advanced Research and Development Authority (BARDA)	43
ANTIVIRAL RESISTANCE	43
RECREATED VIRUSES	44
IMMATERIALIZED MARKET RISK	45
MEDIA COVERAGE AND VACCINATIONS	45
EPIDEMIC/PANDEMIC THREAT	46
<i>TABLE 16 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA, SEVERE OUTBREAKS BASED ON 2017-PROJECTED POPULATION (U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES) (THOUSANDS)</i>	46
PANDEMIC PREPAREDNESS PLANS	48
<i>TABLE 17 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN</i>	48
INFRARED SENSORS AND THERMAL IMAGERS	49
THE UNITED STATES	50
JAPAN	50
<i>TABLE 18 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS</i>	51
CHINA	52
<i>TABLE 19 CHINA'S INFLUENZA PANDEMIC WARNING LEVELS</i>	53
BRAZIL	53
<i>TABLE 20 BRAZIL'S INFLUENZA PANDEMIC WARNING LEVELS AND ACTION</i>	53
UNITED KINGDOM	54
WORLD INFLUENZA IMPACT	55
CHAPTER 5 PATENT ANALYSIS	57
OVERVIEW	57
INFLUENZA PATENTS BY PATENT NUMBER	57
<i>TABLE 21 PATENTS FOR INFLUENZA, BY YEAR ISSUED, 2002-2016</i>	58
<i>FIGURE 12 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2016</i>	58
<i>TABLE 22 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY, BY PATENT NUMBER</i>	59
<i>TABLE 23 NUMBER OF U.S. PATENTS BY INFLUENZA MARKET COMPETITOR</i>	62
EMORY UNIVERSITY	63
GLAXOSMITHKLINE BIOLOGICALS SA	63
LONGHORN VACCINES AND DIAGNOSTICS LLC	64
NOVARTIS	64
NOVAVAX	64
SHIONOGI & CO. LTD.	64
ST. JUDE CHILDREN'S RESEARCH HOSPITAL	64
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES	64

TOPIC	PAGE NO.
UNIVERSITY OF PENNSYLVANIA	65
VERTEX PHARMACEUTICALS INC.	65
WISCONSIN ALUMNI RESEARCH FOUNDATION	65
CHAPTER 6 INFLUENZA VACCINES	67
OVERVIEW	67
HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S.	67
<i>TABLE 24 INFLUENZA VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2017</i>	67
CURRENT VACCINES	69
ASTRAZENECA - MEDIMMUNE	69
SEQIRUS - CSL	70
GLAXOSMITHKLINE	70
MYLAN	71
NANOTHERAPEUTICS	71
PROTEIN SCIENCES CORP.	71
SANOFI PASTEUR	71
SINOVAC BIOTECH	72
<i>TABLE 25 EXAMPLES OF MARKETED SEASONAL INFLUENZA VACCINE PRODUCTS</i>	72
SEASONAL 2016-2017 VACCINE APPROVALS BY FDA	72
<i>TABLE 26 SEASONAL INFLUENZA VACCINE FDA APPROVALS BASED ON ADULT DOSAGE, 2016-2017</i>	73
PANDEMIC INFLUENZA VACCINES	73
<i>TABLE 27 EXAMPLES OF APPROVED PANDEMIC INFLUENZA VACCINE PRODUCTS</i>	73
VACCINE DEVELOPMENTS	74
CLINICAL TRIALS	74
<i>TABLE 28 CLINICAL TRIALS FOR INFLUENZA PREVENTION (VACCINES AND BIOLOGICS) BY SELECTED COUNTRY AND TRIAL STATUS</i>	74
BIKEN	75
<i>TABLE 29 BIKEN INFLUENZA VACCINE PIPELINE</i>	75
BiondVax Pharmaceuticals	75
<i>TABLE 30 BIONDVAX PHARMACEUTICALS INFLUENZA VACCINE PIPELINE</i>	75
Changchun BCHT Biotechnology Co.	76
<i>TABLE 31 CHANGCHUN BCHT BIOTECHNOLOGY INFLUENZA VACCINE PIPELINE</i>	76
Eurocine Vaccines AB	76
<i>TABLE 32 EUROCINE VACCINES INFLUENZA VACCINE PIPELINE</i>	76
Institute of Vaccines and Medical Biologicals, Vietnam	76
<i>TABLE 33 INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS, VIETNAM INFLUENZA VACCINE PIPELINE</i>	77
Longeveron LLC	77
<i>TABLE 34 LONGEVERON LLC INFLUENZA VACCINE PIPELINE</i>	77
MedImmune	77
<i>TABLE 35 MEDIMMUNE INFLUENZA VACCINE PIPELINE</i>	77
Mitsubishi Tanabe	78
<i>TABLE 36 MITSUBISHI TANABE'S INFLUENZA VACCINE PIPELINE</i>	78
NanoBio Corp.	78
<i>TABLE 37 NANOBIO CORP. INFLUENZA VACCINE PIPELINE</i>	78
Nanotherapeutics Inc.	79

TOPIC	PAGE NO.
<i>TABLE 38 NANOTHERAPEUTICS' INFLUENZA VACCINE PIPELINE</i>	79
NanoViricides Inc.	79
<i>TABLE 39 NANOVIRICIDES INFLUENZA VACCINE PIPELINE</i>	80
NexBio Inc.	80
<i>TABLE 40 NEXBIO CORPORATION INFLUENZA VACCINE PIPELINE</i>	80
Nitto Denko Corporation	80
<i>TABLE 41 NITTO DENKO CORPORATION INFLUENZA VACCINE PIPELINE</i>	80
Novavax, Inc.	81
<i>TABLE 42 NOVAVAX INFLUENZA VACCINE PIPELINE</i>	81
Pantec Biosolutions AG	81
PaxVax Corp.	81
<i>TABLE 43 PAXVAX CORPORATION INFLUENZA VACCINE PIPELINE</i>	81
PepTcell Limited	82
<i>TABLE 44 PEPTCELL LTD. INFLUENZA VACCINE PIPELINE</i>	82
Protein Sciences Corp.	82
<i>TABLE 45 PROTEIN SCIENCES INFLUENZA VACCINE PIPELINE</i>	82
Sanofi Pasteur	82
<i>TABLE 46 SANOFI PASTEUR INFLUENZA VACCINE PIPELINE</i>	83
Seqirus	83
<i>TABLE 47 SEQIRUS INFLUENZA VACCINE PIPELINE</i>	83
Vaxart Inc.	83
<i>TABLE 48 VAXART INFLUENZA VACCINE PIPELINE</i>	84
THE GLOBAL INFLUENZA VACCINE MARKET	84
<i>TABLE 49 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)</i>	84
<i>FIGURE 13 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)</i>	85
Seasonal vs. Pandemic Sales	85
<i>FIGURE 14 GLOBAL MARKET FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2016 (\$ MILLIONS)</i>	86
REGIONAL MARKET SUMMARY	87
<i>TABLE 50 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	87
<i>FIGURE 15 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, 2010-2021 (\$ MILLIONS)</i>	87
<i>FIGURE 16 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES, BY REGION, 2016 (%)</i>	88
The U.S. Influenza Vaccine Market	89
<i>TABLE 51 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)</i>	90
<i>FIGURE 17 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2021 (\$ MILLIONS)</i>	90
<i>TABLE 52 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S., BY SEASON, 2005-2017</i>	90
<i>FIGURE 18 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2017 (MILLIONS)</i>	91
<i>TABLE 53 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S., BY MANUFACTURER, 2016-2017 (UNITS PER MILLION/%)</i>	92
The European Influenza Vaccine Market	92
<i>TABLE 54 ESTIMATED INFLUENZA VACCINE SALES DISTRIBUTION IN EU, BY COUNTRY, 2016-2017 (%)</i>	92

TOPIC	PAGE NO.
<i>TABLE 55 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)</i>	93
<i>FIGURE 19 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)</i>	93
GLOBAL COMPETITOR ANALYSIS	94
<i>TABLE 56 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013-2016 (%)</i>	95
<i>FIGURE 20 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013 (%)</i>	95
<i>FIGURE 21 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2014 (%)</i>	95
<i>FIGURE 22 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2015 (%)</i>	96
<i>FIGURE 23 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2016 (%)</i>	96
CHAPTER 7 INFLUENZA THERAPIES	99
OVERVIEW	99
CURRENT THERAPIES	99
DAIICHI SANKYO	99
GLAXOSMITHKLINE	99
ROCHE	99
BIOCRYST PHARMACEUTICALS/SEQIRUS	100
OTHERS	100
<i>TABLE 57 MARKETED THERAPIES, BY COMPANY, 2016</i>	100
GENERIC AVAILABILITY	101
<i>TABLE 58 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS</i>	101
INFLUENZA TREATMENT DEVELOPMENTS	102
CLINICAL TRIALS	102
<i>TABLE 59 CLINICAL TRIALS FOR INFLUENZA THERAPEUTICS, BY SELECTED COUNTRY AND TRIAL STATUS</i>	102
Amarillo Biosciences Inc.	103
<i>TABLE 60 AMARILLO BIOSCIENCES INFLUENZA TREATMENT PIPELINE</i>	103
AstraZeneca (MedImmune)	104
<i>TABLE 61 ASTRAZENECA INFLUENZA TREATMENT PIPELINE</i>	104
Genentech	104
<i>TABLE 62 GENENTECH INFLUENZA TREATMENT PIPELINE</i>	104
GlaxoSmithKline	104
<i>TABLE 63 GLAXOSMITHKLINE INFLUENZA TREATMENT PIPELINE</i>	105
Hemispherx Biopharma	105
<i>TABLE 64 HEMISPHERX BIOPHARMA INFLUENZA TREATMENT PIPELINE</i>	105
Il-Yang Pharm	105
<i>TABLE 65 IL-YANG INFLUENZA TREATMENT PIPELINE</i>	106
Janssen Pharmaceutical Company	106
<i>TABLE 66 JANSSEN PHARMACEUTICAL CO. INFLUENZA TREATMENT PIPELINE</i>	106
Materia Medica Holding	106
<i>TABLE 67 MATERIA MEDICA INFLUENZA TREATMENT PIPELINE</i>	106
Romark Laboratories	106
<i>TABLE 68 ROMARK LABORATORIES INFLUENZA TREATMENT PIPELINE</i>	107

TOPIC	PAGE NO.
Sarepta Therapeutics	107
<i>TABLE 69 SAREPTA THERAPEUTICS INFLUENZA TREATMENT PIPELINE</i>	107
Shionogi	107
<i>TABLE 70 SHIONOGI INFLUENZA TREATMENT PIPELINE</i>	108
Toyama Chemical	108
<i>TABLE 71 TOYAMA CHEMICAL INFLUENZA TREATMENT PIPELINE</i>	108
Visterra Inc.	108
<i>TABLE 72 VISTERRA INFLUENZA TREATMENT PIPELINE</i>	109
THE GLOBAL INFLUENZA THERAPEUTICS MARKET	109
<i>TABLE 73 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)</i>	110
<i>FIGURE 24 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)</i>	110
REGIONAL MARKET SUMMARY	110
<i>TABLE 74 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	111
<i>FIGURE 25 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, 2010-2021 (\$ MILLIONS)</i>	111
<i>FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES, BY REGION, 2016 (%)</i>	112
COMPETITOR ANALYSIS	112
<i>TABLE 75 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013-2016 (%)</i>	113
<i>FIGURE 27 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013 (%)</i>	113
<i>FIGURE 28 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2014 (%)</i>	113
<i>FIGURE 29 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2015 (%)</i>	114
<i>FIGURE 30 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2016 (%)</i>	114
CHAPTER 8 INFLUENZA DIAGNOSTICS	117
OVERVIEW	117
<i>TABLE 76 INFLUENZA DIAGNOSTIC TABLE</i>	117
TEST DESCRIPTIONS[2]	118
Viral Culture	118
Rapid Influenza Diagnostic Tests	119
<i>TABLE 77 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING HIGH INFLUENZA PREVALENCE</i>	119
<i>TABLE 78 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING LOW INFLUENZA PREVALENCE</i>	120
Serologic Testing	120
PRODUCT DESCRIPTION	120
Alere	121
Becton Dickinson	121
BTNX Inc.	121
Cepheid	122
Hologic Inc.	122
Luminex Corp.	122

TOPIC	PAGE NO.
Meridian Biosciences Inc.	122
OraSure Technologies	123
Qiagen	123
Quidel Corp.	123
Remel Inc. (Thermo Scientific)	123
Response Biomedical Corp.	124
SA Scientific Ltd.	124
Sekisui Diagnostics	124
Thermo Fisher Scientific	124
<i>TABLE 79 SELECTED MARKETED RAPID TEST PRODUCTS, DECEMBER 2016</i>	124
<i>TABLE 80 AVERAGE PRICE OF SELECTED RAPID INFLUENZA TESTS (\$)</i>	127
LABORATORY SERVICES	127
Associated Regional University Pathologists (ARUP) Laboratories	127
Bio-Reference Laboratories Inc.	127
Laboratory Corp. of America	127
Pathology Associates Medical Laboratories	128
Quest Diagnostics	128
<i>TABLE 81 PROVIDERS OF TEST SERVICES</i>	128
MARKET ANALYSIS	128
<i>TABLE 82 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)</i>	129
<i>FIGURE 31 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, 2010-2021 (\$ MILLIONS)</i>	129
<i>FIGURE 32 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY PRODUCT CLASSIFICATION, 2016 (%)</i>	130
<i>FIGURE 33 DISTRIBUTION OF CONVENTIONAL LABORATORY INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)</i>	131
<i>FIGURE 34 DISTRIBUTION OF RAPID INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)</i>	131
REGIONAL MARKET SUMMARY	132
<i>TABLE 83 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	132
<i>FIGURE 35 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, 2010-2021 (\$ MILLIONS)</i>	132
<i>FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2016 (%)</i>	133
<i>TABLE 84 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*</i>	134
<i>FIGURE 37 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*</i>	134
COMPETITOR ANALYSIS	135
<i>TABLE 85 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013-2016 (%)</i>	135
<i>FIGURE 38 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013 (%)</i>	136
<i>FIGURE 39 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2014 (%)</i>	136
<i>FIGURE 40 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2015 (%)</i>	136

TOPIC	PAGE NO.
<i>FIGURE 41 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2016 (%)</i>	137
CHAPTER 9 INFLUENZA MARKET SUMMARY	139
OVERVIEW OF INFLUENZA MARKET TRENDS	139
<i>TABLE 86 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS</i>	139
<i>TABLE 87 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS</i>	139
<i>TABLE 88 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS</i>	140
TOTAL MARKET ANALYSIS	140
<i>TABLE 89 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 (\$ MILLIONS)</i>	140
<i>FIGURE 42 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 (\$ MILLIONS)</i>	141
<i>FIGURE 43 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2016 (%)</i>	141
REGIONAL MARKET SUMMARY	142
<i>TABLE 90 GLOBAL INFLUENZA MARKET, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	142
<i>FIGURE 44 GLOBAL INFLUENZA MARKET, BY REGION, 2010-2021 (\$ MILLIONS)</i>	143
<i>FIGURE 45 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REGION, 2016 (%)</i>	143
CHAPTER 10 COMPANY PROFILES	146
SIGNIFICANT COMPANY ACQUISITIONS	146
ALERE INC.	147
<i>TABLE 91 ALERE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	147
<i>FIGURE 46 ALERE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	147
ASTRAZENECA/MEDIMMUNE	148
<i>TABLE 92 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	148
<i>FIGURE 47 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	149
BECTON DICKINSON AND COMPANY	149
<i>TABLE 93 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	150
<i>FIGURE 48 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	150
CEPHEID	150
<i>TABLE 94 DANAHER'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	151
<i>FIGURE 49 DANAHER'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	151
DAIICHI SANKYO	151
<i>TABLE 95 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	152
<i>FIGURE 50 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	152
GLAXOSMITHKLINE PLC	152
<i>TABLE 96 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	153
<i>FIGURE 51 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	153
HOLOGIC INC.	154
<i>TABLE 97 HOLOGIC'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	154
<i>FIGURE 52 HOLOGIC'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	154
MITSUBISHI TANABE PHARMA CORP.	155
<i>TABLE 98 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	155
<i>FIGURE 53 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	155
MYLAN N.V.	156
<i>TABLE 99 MYLAN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	157

TOPIC	PAGE NO.
<i>FIGURE 54 MYLAN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	157
ORASURE TECHNOLOGIES	157
<i>TABLE 100 ORASURE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	158
<i>FIGURE 55 ORASURE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	158
PROTEIN SCIENCES CORPORATION	158
QIAGEN N.V.	159
<i>TABLE 101 QIAGEN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	159
<i>FIGURE 56 QIAGEN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	159
QUIDEL CORP.	160
<i>TABLE 102 QUIDEL'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	161
<i>FIGURE 57 QUIDEL'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	161
ROCHE LTD.	161
<i>TABLE 103 ROCHE GROUP'S REVENUES, 2013-2016 (\$ MILLIONS)</i>	162
<i>FIGURE 58 ROCHE GROUP'S REVENUES, 2013-2016 (\$ MILLIONS)</i>	162
SANOFI/SANOFI PASTEUR	162
<i>TABLE 104 SANOFI'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	163
<i>FIGURE 59 SANOFI'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)</i>	164
SEKISUI DIAGNOSTICS LLC	164
<i>TABLE 105 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* (\$ BILLIONS)</i>	165
<i>FIGURE 60 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* (\$ BILLIONS)</i>	165
SEQIRUS CSL LIMITED	165
<i>TABLE 106 CSL LIMITED'S COMPANY REVENUES, 2013-2016* (\$ MILLIONS)</i>	166
<i>FIGURE 61 CSL LIMITED'S COMPANY REVENUES, 2013-2016* (\$ MILLIONS)</i>	166
CHAPTER 11 APPENDICES	168
APPENDIX I	168
MANUFACTURERS AND DEVELOPERS	168
APPENDIX II	177
<i>TABLE 107 APPROVED WHO INFLUENZA CENTERS BY REGION</i>	178
APPENDIX III	199
GLOSSARY OF TERMS[3]	199
LIST OF ACRONYMS	201

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 DISTRIBUTION OF FATAL CASES OF H1N1 PANDEMIC BY WHO REGIONS, 2009-2010	11
TABLE 2 CDC ESTIMATES OF 2009 H1N1 CASES AND RELATED HOSPITALIZATIONS AND DEATHS, BY AGE GROUP, APRIL 2009 - MARCH 13, 2010	12
TABLE 3 CUMULATIVE NUMBER OF CONFIRMED CASES OF H7N9, BY REGION, OCTOBER 2016	13
TABLE 4 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)	18
TABLE 5 INFLUENZA VIRUS RECOMMENDATIONS FOR U.S. INFLUENZA SEASONS, 2003-2017	20
TABLE 6 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)	22
TABLE 7 CDC INFLUENZA VACCINE RECOMMENDATIONS FOR ALL PEOPLE FROM 6 MONTHS OF AGE	23
TABLE 8 ADJUSTED VACCINE EFFECTIVENESS ESTIMATES FOR INFLUENZA SEASONS, 2005-2016	25
TABLE 9 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)	28
TABLE 10 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)	29
TABLE 11 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2020	29
TABLE 12 GLOBAL LIFE EXPECTANCY AT BIRTH, BY SELECTED COUNTRY, 1980-2020 (YEARS)	31
TABLE 13 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP, APRIL 2009-2010	32
TABLE 14 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS	37
TABLE 15 WHO-REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS	39
TABLE 16 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA, SEVERE OUTBREAKS BASED ON 2017-PROJECTED POPULATION (U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES) (THOUSANDS)	46
TABLE 17 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN	48
TABLE 18 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS	51
TABLE 19 CHINA'S INFLUENZA PANDEMIC WARNING LEVELS	53
TABLE 20 BRAZIL'S INFLUENZA PANDEMIC WARNING LEVELS AND ACTION	53
TABLE 21 PATENTS FOR INFLUENZA, BY YEAR ISSUED, 2002-2016	58
TABLE 22 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY, BY PATENT NUMBER	59
TABLE 23 NUMBER OF U.S. PATENTS BY INFLUENZA MARKET COMPETITOR	62
TABLE 24 INFLUENZA VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2017	67
TABLE 25 EXAMPLES OF MARKETED SEASONAL INFLUENZA VACCINE PRODUCTS	72
TABLE 26 SEASONAL INFLUENZA VACCINE FDA APPROVALS BASED ON ADULT DOSAGE, 2016-2017	73
TABLE 27 EXAMPLES OF APPROVED PANDEMIC INFLUENZA VACCINE PRODUCTS	73
TABLE 28 CLINICAL TRIALS FOR INFLUENZA PREVENTION (VACCINES AND BIOLOGICS) BY SELECTED COUNTRY AND TRIAL STATUS	74
TABLE 29 BIKEN INFLUENZA VACCINE PIPELINE	75

TABLE HEADING	PAGE NO.
TABLE 30 BIONDVAX PHARMACEUTICALS INFLUENZA VACCINE PIPELINE	75
TABLE 31 CHANGCHUN BCHT BIOTECHNOLOGY INFLUENZA VACCINE PIPELINE	76
TABLE 32 EUROCINE VACCINES INFLUENZA VACCINE PIPELINE	76
TABLE 33 INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS, VIETNAM INFLUENZA VACCINE PIPELINE	77
TABLE 34 LONGEVERON LLC INFLUENZA VACCINE PIPELINE	77
TABLE 35 MEDIMMUNE INFLUENZA VACCINE PIPELINE	77
TABLE 36 MITSUBISHI TANABE'S INFLUENZA VACCINE PIPELINE	78
TABLE 37 NANOBIO CORP. INFLUENZA VACCINE PIPELINE	78
TABLE 38 NANOTHERAPEUTICS' INFLUENZA VACCINE PIPELINE	79
TABLE 39 NANOVICIDES INFLUENZA VACCINE PIPELINE	80
TABLE 40 NEXBIO CORPORATION INFLUENZA VACCINE PIPELINE	80
TABLE 41 NITTO DENKO CORPORATION INFLUENZA VACCINE PIPELINE	80
TABLE 42 NOVAVAX INFLUENZA VACCINE PIPELINE	81
TABLE 43 PAXVAX CORPORATION INFLUENZA VACCINE PIPELINE	81
TABLE 44 PEPTCELL LTD. INFLUENZA VACCINE PIPELINE	82
TABLE 45 PROTEIN SCIENCES INFLUENZA VACCINE PIPELINE	82
TABLE 46 SANOFI PASTEUR INFLUENZA VACCINE PIPELINE	83
TABLE 47 SEQIRUS INFLUENZA VACCINE PIPELINE	83
TABLE 48 VAXART INFLUENZA VACCINE PIPELINE	84
TABLE 49 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)	84
TABLE 50 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)	87
TABLE 51 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)	90
TABLE 52 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S., BY SEASON, 2005-2017	90
TABLE 53 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S., BY MANUFACTURER, 2016-2017 (UNITS PER MILLION/%)	92
TABLE 54 ESTIMATED INFLUENZA VACCINE SALES DISTRIBUTION IN EU, BY COUNTRY, 2016-2017 (%)	92
TABLE 55 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)	93
TABLE 56 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013-2016 (%)	95
TABLE 57 MARKETED THERAPIES, BY COMPANY, 2016	100
TABLE 58 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS	101
TABLE 59 CLINICAL TRIALS FOR INFLUENZA THERAPEUTICS, BY SELECTED COUNTRY AND TRIAL STATUS	102
TABLE 60 AMARILLO BIOSCIENCES INFLUENZA TREATMENT PIPELINE	103
TABLE 61 ASTRAZENECA INFLUENZA TREATMENT PIPELINE	104
TABLE 62 GENENTECH INFLUENZA TREATMENT PIPELINE	104
TABLE 63 GLAXOSMITHKLINE INFLUENZA TREATMENT PIPELINE	105
TABLE 64 HEMISPHERX BIOPHARMA INFLUENZA TREATMENT PIPELINE	105
TABLE 65 IL-YANG INFLUENZA TREATMENT PIPELINE	106
TABLE 66 JANSSEN PHARMACEUTICAL CO. INFLUENZA TREATMENT PIPELINE	106
TABLE 67 MATERIA MEDICA INFLUENZA TREATMENT PIPELINE	106
TABLE 68 ROMARK LABORATORIES INFLUENZA TREATMENT PIPELINE	107
TABLE 69 SAREPTA THERAPEUTICS INFLUENZA TREATMENT PIPELINE	107

TABLE HEADING	PAGE NO.
TABLE 70 SHIONOGI INFLUENZA TREATMENT PIPELINE	108
TABLE 71 TOYAMA CHEMICAL INFLUENZA TREATMENT PIPELINE	108
TABLE 72 VISTERRA INFLUENZA TREATMENT PIPELINE	109
TABLE 73 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, THROUGH 2021 (\$ MILLIONS)	110
TABLE 74 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)	111
TABLE 75 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013-2016 (%)	113
TABLE 76 INFLUENZA DIAGNOSTIC TABLE	117
TABLE 77 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING HIGH INFLUENZA PREVALENCE	119
TABLE 78 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING LOW INFLUENZA PREVALENCE	120
TABLE 79 SELECTED MARKETED RAPID TEST PRODUCTS, DECEMBER 2016	124
TABLE 80 AVERAGE PRICE OF SELECTED RAPID INFLUENZA TESTS (\$)	127
TABLE 81 PROVIDERS OF TEST SERVICES	128
TABLE 82 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)	129
TABLE 83 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)	132
TABLE 84 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*	134
TABLE 85 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013-2016 (%)	135
TABLE 86 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS	139
TABLE 87 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS	139
TABLE 88 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS	140
TABLE 89 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 (\$ MILLIONS)	140
TABLE 90 GLOBAL INFLUENZA MARKET, BY REGION, THROUGH 2021 (\$ MILLIONS)	142
TABLE 91 ALERE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	147
TABLE 92 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	148
TABLE 93 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	150
TABLE 94 DANAHER'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	151
TABLE 95 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	152
TABLE 96 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	153
TABLE 97 HOLOGIC'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	154
TABLE 98 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	155
TABLE 99 MYLAN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	157
TABLE 100 ORASURE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	158
TABLE 101 QIAGEN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	159
TABLE 102 QUIDEL'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	161
TABLE 103 ROCHE GROUP'S REVENUES, 2013-2016 (\$ MILLIONS)	162
TABLE 104 SANOFI'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	163
TABLE 105 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* (\$ BILLIONS)	165
TABLE 106 CSL LIMITED'S COMPANY REVENUES, 2013-2016* (\$ MILLIONS)	166
TABLE 107 APPROVED WHO INFLUENZA CENTERS BY REGION	178

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 (\$ MILLIONS)	7
FIGURE 1 WORLDWIDE INFLUENZA ACTIVITY OCTOBER 2014 - MAY 2015	16
FIGURE 2 WORLDWIDE INFLUENZA ACTIVITY MAY 2015 - SEPTEMBER 2015	16
FIGURE 3 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)	19
FIGURE 4 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS ALLERGIC TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES FOR U.S. INFLUENZA SEASON, 2015-2016	24
FIGURE 5 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)	28
FIGURE 6 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)	29
FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010- 2020 (MILLIONS)	30
FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2020 (YEARS)	31
FIGURE 9 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS, 2003-2016* (NO.)	39
FIGURE 10 APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)	40
FIGURE 11 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS FOR SELECTED COUNTRIES (MILLION)	42
FIGURE 12 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2016	58
FIGURE 13 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)	85
FIGURE 14 GLOBAL MARKET FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2016 (\$ MILLIONS)	86
FIGURE 15 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, 2010-2021 (\$ MILLIONS)	87
FIGURE 16 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES, BY REGION, 2016 (%)	88
FIGURE 17 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2021 (\$ MILLIONS)	90
FIGURE 18 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2017 (MILLIONS)	91
FIGURE 19 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)	93
FIGURE 20 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013 (%)	95
FIGURE 21 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2014 (%)	95
FIGURE 22 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2015 (%)	96
FIGURE 23 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2016 (%)	96
FIGURE 24 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, 2010-2021 (\$ MILLIONS)	110
FIGURE 25 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, 2010-2021 (\$ MILLIONS)	111
FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES, BY REGION, 2016 (%)	112
FIGURE 27 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013 (%)	113

FIGURE TITLE	PAGE NO.
FIGURE 28 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2014 (%)	113
FIGURE 29 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2015 (%)	114
FIGURE 30 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2016 (%)	114
FIGURE 31 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, 2010-2021 (\$ MILLIONS)	129
FIGURE 32 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY PRODUCT CLASSIFICATION, 2016 (%)	130
FIGURE 33 DISTRIBUTION OF CONVENTIONAL LABORATORY INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)	131
FIGURE 34 DISTRIBUTION OF RAPID INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)	131
FIGURE 35 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, 2010-2021 (\$ MILLIONS)	132
FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2016 (%)	133
FIGURE 37 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*	134
FIGURE 38 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013 (%)	136
FIGURE 39 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2014 (%)	136
FIGURE 40 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2015 (%)	136
FIGURE 41 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2016 (%)	137
FIGURE 42 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 (\$ MILLIONS)	141
FIGURE 43 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2016 (%)	141
FIGURE 44 GLOBAL INFLUENZA MARKET, BY REGION, 2010-2021 (\$ MILLIONS)	143
FIGURE 45 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REGION, 2016 (%)	143
FIGURE 46 ALERE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	147
FIGURE 47 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	149
FIGURE 48 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	150
FIGURE 49 DANAHER'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	151
FIGURE 50 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	152
FIGURE 51 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	153
FIGURE 52 HOLOGIC'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	154
FIGURE 53 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	155
FIGURE 54 MYLAN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	157
FIGURE 55 ORASURE'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	158
FIGURE 56 QIAGEN'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	159
FIGURE 57 QUIDEL'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	161
FIGURE 58 ROCHE GROUP'S REVENUES, 2013-2016 (\$ MILLIONS)	162
FIGURE 59 SANOFI'S COMPANY REVENUES, 2013-2016 (\$ MILLIONS)	164
FIGURE 60 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* (\$ BILLIONS)	165
FIGURE 61 CSL LIMITED'S COMPANY REVENUES, 2013-2016* (\$ MILLIONS)	166